<DOC>
	<DOCNO>NCT01689376</DOCNO>
	<brief_summary>The purpose Managed Access Program provide regorafenib patient diagnose metastatic / unresectable GIST progress standard therapy .</brief_summary>
	<brief_title>Regorafenib Subjects With Gastrointestinal Stromal Tumors ( GIST ) Who Have Progressed After Standard Therapy ( Managed Access Program )</brief_title>
	<detailed_description>This `` Managed Access Program '' cover different type program participate country ( include compassionate use program , name patient program , cohorts e.g . ATU France , etc ) .</detailed_description>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<criteria>Signed Informed consent ( IC ) data protection clarification obtain specific treatment related procedure . Patients legal representative must able understand willing sign write IC . Male female patient &gt; = 18 year age Patients histologically confirm metastatic / unresectable GIST At least imatinib sunitinib prior treatment regimen progression intolerance imatinib sunitinib Eastern Cooperative Oncology Group ( ECOG ) Performance Status = &lt; 1 Adequate bone marrow , liver renal function Women childbearing potential men must agree use adequate contraception enter program least 8 week last regorafenib administration program . The treat physician designate associate request advise patient achieve adequate birth control . Adequate contraception define program medically recommend method ( combination method ) per standard care . Prior treatment regorafenib Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior start regorafenib Pregnant breastfeeding patient . Women childbearing potential must pregnancy test perform maximum 7 day start treatment , negative result must document start regorafenib . Congestive heart failure New York Heart Association ( NYHA ) class 2 Unstable angina ( angina symptom rest ) , newonset angina ( begin within last 3 month ) Myocardial infarction le 6 month start regorafenib Cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) Uncontrolled hypertension . ( Systolic blood pressure &gt; 140 mmHg diastolic pressure &gt; 90 mmHg despite optimal medical management ) Pleural effusion ascites cause respiratory compromise ( National Cancer Institute 's common terminology criterion adverse event [ NCICTCAE ] v.4.0 Grade &gt; = 2 dyspnea ) Ongoing infection NCICTCAE v.4.0 Grade &gt; 2 Known history human immunodeficiency virus ( HIV ) infection Active hepatitis B C , chronic hepatitis B C require treatment antiviral therapy Patients seizure disorder require medication History organ allograft Patients evidence history bleed diathesis , irrespective severity Any hemorrhage bleeding event NCICTCAE v. 4.0 Grade &gt; = 3 within 4 week prior start regorafenib Nonhealing wound , ulcer , bone fracture Renal failure require hemo peritoneal dialysis Dehydration NCICTCAE v.4.0 Grade &gt; = 1 Substance abuse , medical , psychological social condition may interfere patient 's participation program Known hypersensitivity regorafenib , drug class , excipients formulation Any illness medical condition unstable could jeopardize safety patient / compliance program Interstitial lung disease ongoing sign symptom Persistent proteinuria NCICTCAE v.4.0 Grade 3 ( &gt; 3.5 g/24 hour ) Patients unable swallow oral medication Any malabsorption condition Unresolved toxicity high NCICTCAE v.4.0 Grade 1 ( exclude alopecia , anaemia , hypothyroidism ) attribute prior therapy / procedure Concomitant participation participation within last 30 day clinical trial Nonpermissible concomitant medication procedure ( systemic anticancer therapy include cytotoxic therapy , signal transduction inhibitor , immunotherapy hormonal therapy experimental therapy ; Tyrosine Kinase Inhibitors ( TKIs ) ; bone marrow transplant stem cell rescue ; use biologic response modifier , granulocyte colony stimulate factor ( G CSF ) , within 3 week prior enter program ; St John 's Wort ; grapefruit grapefruit juice ; traditional medicine anticancer indication )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>